Free tool
FDA Approval Tracker
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
Matching approvals
1,397
2012 to 2026
Breakthrough
234
Accelerated
121
Priority review
759
Orphan
1397
By year
NDAs and BLAs matching the filters.
- NDA
- BLA
View as table
| Year | NDA | BLA |
|---|---|---|
| 2012 | 25 | 4 |
| 2013 | 24 | 6 |
| 2014 | 37 | 15 |
| 2015 | 41 | 17 |
| 2016 | 39 | 20 |
| 2017 | 74 | 26 |
| 2018 | 88 | 42 |
| 2019 | 74 | 26 |
| 2020 | 79 | 47 |
| 2021 | 67 | 30 |
| 2022 | 67 | 27 |
| 2023 | 77 | 41 |
| 2024 | 84 | 52 |
| 2025 | 101 | 63 |
| 2026 | 60 | 44 |
1,397 approvals
Newest first. Hover a badge for what it means.
- Klygefa (Gefurulimab) · Alexion PharmNov 13, 2026Original approval · BLA 761488NovelOrphan
To treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis
- Myqorzo (Aficamten) · CytokineticsNov 13, 2026Efficacy supplement 2 · NDA 219083Orphan
- Skyrizi (Risankizumab-Rzaa) · Abbvie INCOct 23, 2026
- Ultomiris (Ravulizumab-Cwvz) · Alexion PharmOct 21, 2026
- Ayvakit (Avapritinib) · Blueprint MedicinesOct 16, 2026
- Keytruda (Pembrolizumab) · Merck Sharp DohmeOct 16, 2026
- Zilbrysq (Zilucoplan Sodium) · Ucb INCOct 15, 2026
- Repatha (Evolocumab) · Amgen INCOct 9, 2026
- Tukysa (Tucatinib) · SeagenOct 7, 2026
- Jaypirca (Pirtobrutinib) · Loxo OncolOct 2, 2026
- Camzyos (Mavacamten) · BristolSep 30, 2026
- Emcitate (Tiratricol) · Rare ThyroidSep 28, 2026
To treat peripheral thyrotoxicosis in patients with MCT8 deficiency
- Atebrioz (Zilurgisertib Fumarate) · MirumSep 25, 2026
To reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva
- Gazyva (Obinutuzumab) · GenentechSep 25, 2026
- Lenvima (Lenvatinib Mesylate) · Eisai INCSep 24, 2026
- Lyrfigtu (Lirafugratinib Hydrochloride) · ElevarSep 23, 2026
To adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement
- Winrevair (Sotatercept-Csrk) · Merck Sharp DohmeSep 21, 2026
- Aqneursa (Levacetylleucine) · IntrabioSep 18, 2026
- Ibtrozi (Taletrectinib Adipate) · NuvationSep 16, 2026
- Tagrisso (Osimertinib Mesylate) · AstrazenecaSep 14, 2026
- Isembyld (Apitegromab-Mstn) · Scholar Rock INCSep 11, 2026
To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment
- Joenja (Leniolisib Phosphate) · PharmingSep 11, 2026
- Pixclara (Floretyrosine F-18) · TelixSep 11, 2026
To use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic evaluations
- Hyrnuo (Sevabertinib) · Bayer HealthcareSep 9, 2026
- Zanvastro (Zilganersen Sodium) · Ionis Pharms INCSep 3, 2026
To treat Alexander disease in pediatric and adult patients
- Stelara (Ustekinumab) · Janssen BiotechAug 28, 2026
- Mimrylo (Rusfertide Acetate) · Takeda Pharms AmAug 28, 2026
To treat erythrocytosis in adults with polycythemia vera
- Besremi (Ropeginterferon Alfa-2b-Njft) · Pharmaessentia CorpAug 28, 2026
- Lisraya (Brepocitinib Tosylate) · Priovant TherapAug 27, 2026
To treat dermatomyositis in adults
- Rasonque (Daraxonrasib) · Revolution MedicinesAug 26, 2026
To treat metastatic pancreatic cancer
- Tevimbra (Tislelizumab-Jsgr) · BeigeneAug 25, 2026
- Ziihera (Zanidatamab-Hrii) · Jazz PharmsAug 25, 2026
- Imaavy (Nipocalimab-Aahu) · Janssen BiotechAug 24, 2026
- Empaveli (Pegcetacoplan) · Apellis PharmsAug 20, 2026
- Pasatru (Garetosmab-Grts) · Regeneron Pharmaceuticals, INCAug 19, 2026
To reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva
- Zenbexus (Iberdomide Hydrochloride) · Bristol Myers SquibbAug 13, 2026
To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent
- Orzeyful (Oveporexton) · Takeda Pharms USAAug 5, 2026
To treat narcolepsy type 1
- Zimrixby (Rituximab-Cdxx) · Dr Reddys Labs SAJul 31, 2026
- Macrilen (Macimorelin Acetate) · Aeterna ZentarisJul 23, 2026
- Jideytro (Zidesamtinib) · NuvalentJul 22, 2026
To treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after receiving a ROS1 kinase inhibitor
- Rezzayo (Rezafungin Acetate) · MundipharmaJul 16, 2026
- Retevmo (Selpercatinib) · Eli Lilly and COJul 14, 2026
- Retevmo (Selpercatinib) · Eli Lilly and COJul 14, 2026
- Sarclisa Escena (Isatuximab-Irfc) · Sanofi-Aventis U.S. LLCJul 9, 2026
- Skyrizi (Risankizumab-Rzaa) · Abbvie INCJun 26, 2026
- Tryngolza (Autoinjector) (Olezarsen Sodium) · Ionis Pharms INCJun 24, 2026
- Skyrizi (Risankizumab-Rzaa) · Abbvie INCJun 12, 2026
- Tzield (Teplizumab-Mzwv) · Provention Bio INCJun 12, 2026
- Ambelvist (Gadoquatrane) · Bayer HealthcareJun 12, 2026
To detect and visualize lesions with abnormal vascularity, in conjunction with MRI
- Alecensa (Alectinib Hydrochloride) · Hoffmann-La RocheJun 11, 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.